Greenwich LifeSciences, Inc.
1 clinical trials · Sponsor
◉ Watch Greenwich LifeSciences, Inc.
| Record | Firm | Date |
|---|---|---|
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects (NCT05232916) | Greenwich LifeSciences, Inc. | 2022-12-16 |
Track Greenwich LifeSciences, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.